To Be An Excellent Brand of
Pharmaceutical Intermediates Manufacturer in the world
With the national development and Reform Commission (NDRC) officially issuing the "13th Five-Year" biological industry development plan, biological medicine has a new round of development opportunities. Specific to the bio pharmaceutical industry, it is required to achieve industrial sales income by 4 trillion and 500 billion yuan by 2020, and the added value will account for 3.6% of the national industrial added value. Innovative research and development will have an important impact on this goal. In the 2017 China Pharmaceutical Innovation Summit Forum and the top 100 list of pharmaceutical enterprises' R & D strength, 4 Chinese medical cities entered the 2017 China biodrug R & D list TOP50.
From the information released by the WeChat public of China Medical City, the "2017 China pharmaceutical innovation high peak forum and the top 100 list of research and development strength of pharmaceutical enterprises", sponsored by Chinese pharmacy magazine, was held in Chongqing on -10 September 8th. The conference issued the list of the 2017 China Pharmaceutical Research and development strength list. Including the total list, chemical drug list, Chinese medicine list, biopharmaceutical list, brand list, and on-site Award for awarding the list of enterprises. The Chinese medicine city has entered the enterprise of Jiangsu Tai Kang bio medicine Co., Taizhou macertaike Pharmaceutical Co., Ltd., Jiangsu Kindik Bio Technology Co., Ltd., Taizhou Jun real biomedical Polytron Technologies Inc entered the "2017 China biodrug R & D strength list TOP50".
From the perspective of the whole market, the scale and growth rate of domestic pharmaceutical investment is very fast, especially in the field of biological medicine. In November 29, 2016, XinDa announced the successful completion of D round financing of $260 million (about 1 billion 700 million yuan). The amount of this financing was ranked as the top of the whole biological medicine industry in China in 2016 and the non IPO financing in the world.
As the national development and Reform Commission officially issued the "13th Five-Year biological industry development plan", biomedicine has ushered in a new round of development opportunities. According to the plan, China's bio pharmaceutical industry will focus on the development of many innovative drugs, such as chemical drugs, biotech drugs, new vaccines, new cell therapy preparations, and so on in the period of "13th Five-Year". Specific to the bio pharmaceutical industry, it is required to achieve industrial sales income by 4 trillion and 500 billion yuan by 2020, and the added value will account for 3.6% of the national industrial added value.
According to the statistics of drug intelligence, in 2015 CDE accepted 558 biological products (with the number of admissible numbers, the same), accounting for 6.8% of the total amount of drugs accepted. In 2016, 408 of the biological products were accepted by CDE, accounting for 10.79% of the total admissibility, although the number of biological products has declined, but the proportion in other drugs is rising, so enterprises begin to cloth The market for biologics (as shown in Figure 1, figure 2). The system of drug acceptance, examination and approval and supervision is becoming more and more strict in the state. The decline of the number of biological products is inseparable from the large decline in the amount of all kinds of drugs in 2016. The policy has prompted the drug enterprises to keep the market to make high sharp drugs, and the research and development of biological products is a good choice.